Skip to main content

Quanterix Selects Scrum to Distribute Simoa in Japan

NEW YORK (GenomeWeb) – Quanterix said today that Tokyo-based Scrum will be the exclusive distributor of Quanterix's Simoa technology in the Japanese research market.

Lexington, Mass.-based Quanterix launched Simoa, a single-molecule array immunoassay technology for detecting and quantifying antigens and proteins, in 2013.

"We have experienced strong demand from researchers in Japan for our Simoa technology with several Japanese researcher groups traveling to Boston to access the ultrasensitive single-molecule protein detection technology in our Accelerator Lab," Quanterix CEO Kevin Hrusovsky said in a statement.

He added that Scrum would offer researchers comprehensive sales, applications, and field service support locally in Japan.

Financial and other details of the deal were not disclosed.

"Our customers have been asking about Simoa for over a year now and are very eager to have the ability to measure biomarkers with far greater sensitivity than ever before," Scrum CEO Mikio Fuchigami said.

Earlier this month, Quanterix partnered with Myriad RBM to offer immunoassay services based on the Simoa platform.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.